| NCT07883512 ↗EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction) | Phase 2 | 모집 전 | 중재 1개 · 상세 참조Breast Cancer · Supportive Care in Cancer | 등록 10명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- Empagliflozin
- 등록 질환
- Breast Cancer · Supportive Care in Cancer
- 등록 1차 평가변수
- Evaluate the feasibility of investigating 10 mg/day empagliflozin in breast cancer patients receiving anthracycline-based chemotherapy, including participant recruitment; Evaluate the acceptability of a clinical trial protocol investigating 10 mg/day empagliflozin in breast cancer patients receiving anthracycline-based chemotherapy, including medication adherence; Evaluate the acceptability of a clinical trial protocol investigating 10 mg/day empagliflozin in breast cancer patients receiving ant
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 10
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT04243616 ↗Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer | Phase 2 | 진행 중 · 모집 종료 | 중재 5개 · 상세 참조Invasive Breast Cancer | 등록 36명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- Cemiplimab · Paclitaxel · Carboplatin (not mandatory) · Doxorubicin · Cyclophosphamide
- 등록 질환
- Invasive Breast Cancer
- 등록 1차 평가변수
- The Proportion of Breast Cancer Patients With Pathological Complete Response (pCR).
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 36
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT04561362 ↗Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Phase 1, Phase 2 | 진행 중 · 모집 종료 | 중재 2개 · 상세 참조Urinary Bladder Neoplasm · Triple Negative Breast Neoplasms · Hormone Receptor Positive, HER2-negative Neoplasms · Hormone Receptor Positive, HER2-low Neoplasms · Breast Neoplasms · Non-Small-Cell Lung Neoplasms · Ovarian Neoplasm · Advanced Solid Tumor | 등록 329명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- BT8009 · Pembrolizumab
- 등록 질환
- Urinary Bladder Neoplasm · Triple Negative Breast Neoplasms · Hormone Receptor Positive, HER2-negative Neoplasms · Hormone Receptor Positive, HER2-low Neoplasms · Breast Neoplasms · Non-Small-Cell Lung Neoplasms · Ovarian Neoplasm · Advanced Solid Tumor
- 등록 1차 평가변수
- Parts A-1, A-2 and C: Number of participants with treatment emergent adverse events, receiving BT8009 as a monotherapy or in combination with pembrolizumab to assess safety and tolerability.; Parts A-1 and A-2 (escalations): Number of participants with dose limiting toxicities on BT8009 as a monotherapy or in combination with pembrolizumab; Part B1-B7: Objective response rate (ORR) to assess the clinical activity of BT8009 as a monotherapy or in combination with pembrolizumab using RECIST 1.1.;
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 329
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT06247995 ↗A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | Phase 1, Phase 2 | 진행 중 · 모집 종료 | 중재 3개 · 상세 참조Breast Cancer | 등록 20명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- [68Ga]Ga-NeoB · [177Lu]Lu-NeoB · Capecitabine
- 등록 질환
- Breast Cancer
- 등록 1차 평가변수
- Phase I: Incidence and severity of dose limiting toxicities (DLTs); Phase I: Incidence and severity of adverse events and serious adverse events for 177-Lu-NeoB in combination with capecitabine; Phase I: Dose modifications for [177Lu]Lu-NeoB in combination with capecitabine; Phase II: Objective Response Rate (ORR); Phase II: Clinical Benefit Rate (CBR); Phase II: Time to Response (TTR); Phase II: Duration of Response (DoR); Phase II: Progression Free Survival (PFS); Phase II: Overall Survival (O
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 20
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT07884201 ↗Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment | Phase 2 | 모집 전 | 중재 1개 · 상세 참조Breast Cancer · TNBC - Triple-Negative Breast Cancer · Immunotherapy | 등록 572명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- Thymalfasin
- 등록 질환
- Breast Cancer · TNBC - Triple-Negative Breast Cancer · Immunotherapy
- 등록 1차 평가변수
- EFS; Interferon-gamma (IFNγ) elevation rate
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 572
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT07697443 ↗Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects | Phase 1, Phase 2 | 모집 중 | 중재 1개 · 상세 참조Breast Cancer | 등록 300명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- TQB3126
- 등록 질환
- Breast Cancer
- 등록 1차 평가변수
- Dose Limiting Toxicity (DLT); Maximum Tolerated Dose (MTD); Recommended Phase II Dose (RP2D); Adverse Events (AEs); Serious Adverse Events (SAEs); Abnormal Incidence of Laboratory Test Indicators; Objective Response Rate (ORR); Maximum Applicable Dose (MAD)
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 300
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT06361940 ↗Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer | Phase 2 | 모집 중 | 중재 1개 · 상세 참조Breast Cancer | 등록 185명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- Aromatase inhibitors or tamoxifen
- 등록 질환
- Breast Cancer
- 등록 1차 평가변수
- Change from baseline in the number of subjects with increased HER-1 receptor tyrosine kinases protein expression in tumors.; Change from baseline in the number of subjects with increased HER-2 receptor tyrosine kinases protein expression in tumors.; Change from baseline in the number of subjects with increased HER-3 receptor tyrosine kinases protein expression in tumors.; Change from baseline in the number of subjects with increased HER-4 receptor tyrosine kinases protein expression in tumors.
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 185
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT05544929 ↗A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | Phase 1 | 진행 중 · 모집 종료 | 중재 2개 · 상세 참조Carcinoma, Non-Small-Cell Lung · Cutaneous Melanoma · Carcinoma, Renal Cell · Carcinoma, Ovarian Epithelial · Nasopharyngeal Carcinoma · Carcinoma, Thymic · Anal Cancer · Mesothelioma · Esophagogastric Cancer · High Microsatellite Instability Colorectal Carcinoma · Squamous Cell Carcinoma of Head and Neck · Triple Negative Breast Neoplasms | 등록 126명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- KFA115 · pembrolizumab
- 등록 질환
- Carcinoma, Non-Small-Cell Lung · Cutaneous Melanoma · Carcinoma, Renal Cell · Carcinoma, Ovarian Epithelial · Nasopharyngeal Carcinoma · Carcinoma, Thymic · Anal Cancer · Mesothelioma · Esophagogastric Cancer · High Microsatellite Instability Colorectal Carcinoma · Squamous Cell Carcinoma of Head and Neck · Triple Negative Breast Neoplasms
- 등록 1차 평가변수
- Incidence and severity of dose limiting toxicities (DLTs) during the DLT evaluation period of single-agent KFA115 (dose escalation only); Incidence and severity of dose limiting toxicities (DLTs) during the DLT evaluation period of KFA115 in combination with pembrolizumab (dose escalation only); Incidence and severity of adverse events (AEs) and serious adverse events (SAEs); Frequency of dose interruptions, reductions; Dose intensity
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 126
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT07173751 ↗ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | Phase 3 | 모집 중 | 중재 6개 · 상세 참조Breast Neoplasms | 등록 558명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- Pumitamig · Nab-paclitaxel/Paclitaxel · Gemcitabine · Carboplatin · Eribulin · Matching placebo
- 등록 질환
- Breast Neoplasms
- 등록 1차 평가변수
- Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR); Overall Survival (OS)
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 558
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT07360314 ↗Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors | Phase 1 | 모집 중 | 중재 2개 · 상세 참조Advanced Solid Tumors | 등록 138명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- M7437 · M7437
- 등록 질환
- Advanced Solid Tumors
- 등록 1차 평가변수
- Dose-escalation Cohort: Occurences of Dose Limiting Toxicities (DLTs); Dose-escalation Cohort: Number of Participants With Treatment-Emergent Adverse Event (TEAEs) and Adverse Event (AEs)
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 138
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT05305365 ↗Study Assessing QBS72S For Treating Brain Metastases | Phase 2 | 진행 중 · 모집 종료 | 중재 1개 · 상세 참조Brain Metastases · Breast Cancer · Lung Cancer · Leptomeningeal Disease · LMD | 등록 21명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- QBS72S
- 등록 질환
- Brain Metastases · Breast Cancer · Lung Cancer · Leptomeningeal Disease · LMD
- 등록 1차 평가변수
- Overall Response Against Intracranial Tumor Lesions, Cohort 1- Stage 1
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 21
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|
| NCT06257264 ↗A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | Phase 1 | 진행 중 · 모집 종료 | 중재 3개 · 상세 참조Breast Cancer · Small Cell Lung Cancer · Ovarian Cancer · Gastric Cancer · Hormone-receptor-positive Breast Cancer · Hormone Receptor Positive HER-2 Negative Breast Cancer · Advanced Solid Tumor · Endometrial Cancer · Prostate Cancer · TNBC - Triple-Negative Breast Cancer · GastroEsophageal Cancer · Bladder Cancer | 등록 103명2026-10-20중재명·평가변수·출처 상태- 등록 중재명 · 병용/대조약 포함
- BG-68501 · Fulvestrant · BGB-43395
- 등록 질환
- Breast Cancer · Small Cell Lung Cancer · Ovarian Cancer · Gastric Cancer · Hormone-receptor-positive Breast Cancer · Hormone Receptor Positive HER-2 Negative Breast Cancer · Advanced Solid Tumor · Endometrial Cancer · Prostate Cancer · TNBC - Triple-Negative Breast Cancer · GastroEsophageal Cancer · Bladder Cancer
- 등록 1차 평가변수
- Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs); Part 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-68501; Part 1: Recommended dose(s) for Expansion (RDFE) of BG-68501 monotherapy in participants with solid tumors; Part 1: RDFE of BG-68501 in combination with fulvestrant and BGB-43395 in participants with HR+/HER2- BC; Part 2: Objective Response Rate (ORR)
- 등록 규모 · 분석 대상자 수와 다를 수 있음
- 103
- 등록자료 최종 게시 갱신
- 2026-10-20
|
|---|